Skip to main content
OpenTrials
Completed

NCT Number: NCT00263159

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Ghent

Ghent, 9000, Belgium

About this study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients. Patients will be randomly allocated to the control group (= no input from pharmacist) or intervention group (= with pharmaceutical care at baseline and follow-up visits over 6 months).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with persistent asthma
  • Asthma treatment for at least 12 months
  • Regular visitors of the participating community pharmacy

Exclusion criteria

  • Severe co-morbidity
  • > 10 pack-years smoking history
  • Asthma Control Test score < 15 or =25

Treatment and study plan

Pharmaceutical care for asthma patients

Procedure

Primary outcomes

  1. The difference between study groups in the change of asthma control from baseline and follow-up visits

    Time frame: after 1, 3 and 6 months

Secondary outcomes

  1. Peak flow

    Time frame: after 3 and 6 months

  2. Knowledge of asthma and treatment

    Time frame: after 6 months

  3. Asthma quality of life questionnaire (AQLQ)

    Time frame: after 6 months

  4. Therapy adherence

  5. Inhalation techniques

    Time frame: after 6 months

  6. Smoking

    Time frame: after 6 months

  7. Asthma exacerbations

    Time frame: after 6 months

  8. General Practitioner (GP) visits, emergency room visits and hospitalisations

  9. Working days lost and school days lost

Sponsors and collaborators

Lead sponsor

University Ghent

Other

Registry information

Official study title

Pharmaceutical Care for Asthma Control Improvement

Important dates

Study start
2006
Study completion
2006
First posted
Dec 7, 2005
Registry last updated
Dec 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.